EN
Home/Answers/Eye problems and vision changes
ALLAll countries Side effects and safety

Can tirzepatide or semaglutide affect your eyes or vision?

What we checked12 sources, each one opened and linked to the sentence it supportsLast checked Nov 16, 2026 · Next review due Nov 16, 2027 · How we write
The short answer

Yes, sometimes. Labels for tirzepatide (Mounjaro, Zepbound) and semaglutide (Wegovy) warn that diabetic eye disease can briefly worsen when blood sugar falls fast. Labels in Europe, the UK, Canada and Australia list NAION, a rare cause of sudden vision loss, and the US FDA ordered the same warning in Nov 2026. Blurred vision can signal low blood sugar.

Which eye problems do the labels warn about?

The main eye warning for both medicines is that diabetic eye disease (retinopathy) can get worse for a while when blood sugar improves quickly.123

The US Zepbound label and the EU Mounjaro product information both say this for tirzepatide. Both say people with retinopathy should be monitored.23 The US Wegovy label says the same for semaglutide.1

The US Wegovy label also gives numbers from a 2-year semaglutide trial in type 2 diabetes. Retinopathy complications affected 3% on semaglutide and 1.8% on placebo. The gap was larger in people who already had retinopathy (8.2% vs 5.2%) than in those who didn’t (0.7% vs 0.4%).1

EU Wegovy product information also lists NAION, an optic nerve condition that causes sudden vision loss. In type 2 diabetes studies, it works out at about one extra case per 10,000 person-years of treatment.4 In Nov 2026 the US FDA said NAION has been reported with every GLP-1 medicine on sale, including tirzepatide, and required a warning on all their labels.12 The FDA describes NAION as sudden, painless vision loss in one eye, which people may notice on waking.12 The Australian Mounjaro label calls NAION a rare condition that can reduce vision, sometimes permanently.7

Why might your vision blur?

Blurred vision can be a sign of low blood sugar, a risk the US Wegovy label flags in type 2 diabetes, especially alongside insulin or a sulfonylurea.1

The NHS also lists blurred vision among the symptoms of low blood sugar. It says low blood sugar is rare in people without diabetes.8

The US Wegovy and Zepbound labels both ask people with type 2 diabetes to report any change in vision during treatment.12 We found no study of short-lived blur that settles while people stay on these medicines.

Is dry eye a listed side effect?

Dry eye appears on only one label we checked, the Canadian monograph for semaglutide tablets (Rybelsus), based on type 2 diabetes trials.5

In those trials, 1.7% of people on the 7 mg dose had dry eye, against 0% on 14 mg and 0.3% on placebo.5 We found no dry eye entry in the US Wegovy or Zepbound labels, the EU Wegovy or Mounjaro product information, or the UK Wegovy SmPC.124310

When is a change in your eyes urgent?

Suddenly losing sight in one or both eyes, or sudden severe eye pain, is an emergency, according to the UK NHS; call your local emergency number.9

The NHS advises an urgent appointment for blurred or double vision, flashing lights or shapes, a dark shadow moving across your vision, or a red, painful eye.9

Labels that mention NAION say a sudden loss of vision should lead to an eye examination. Health Canada’s Zepbound monograph adds that this includes partial loss, and that the referral should be urgent.46

What do people on GLP-1 medicines report about their eyes?

From public patient forums: 49 Reddit threads in r/Zepbound, r/Mounjaro, r/Ozempic, r/mounjarouk, r/WegovyWeightLoss and r/glp1, read from October 2025 to October 2026. Personal reports, not medical evidence.

What people describe

  • Not studied Many describe dry, gritty or burning eyes, often soon after starting or after a dose increase. We found no study of when dry eye starts on these medicines. We found dry eye on one label only, for 7 mg semaglutide tablets in Canada (1.7% vs 0.3% on placebo), and on no tirzepatide label.5
  • Not studied Many describe blurred vision or harder focusing in the first weeks, and several say it settled while they stayed on the medicine. We found no study of this pattern.
  • Not studied Several say their eyes stayed the same or improved, including stable diabetic eye disease. We found no study of eyesight improving on these medicines. In one trial reported in the US Wegovy label, retinopathy complications affected 3% on semaglutide and 1.8% on placebo, more often in people who already had retinopathy.1

Advice people share

  • Matches the NHS Many urge getting any eye symptom checked by an optician or eye doctor. The NHS advises an optician for worsening sight and an urgent appointment for blurred or double vision.9
  • Matches the NHS Several say a new shadow or sudden loss of sight in one eye needs same-day care. The NHS lists sudden loss of sight as an emergency.9
  • Matches the US labels Several advise telling the prescriber about any change in vision. The US Wegovy and Zepbound labels say this for people with type 2 diabetes.12
  • NHS says otherwise Several replies put symptoms down to dehydration or anxiety without an eye exam. The NHS advises an urgent appointment for new changes in vision.9

In your country

The diabetic retinopathy warning is the same in every label we opened. NAION wording differs by country, and only one label lists dry eye.

Australia

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.

Label: The Australian Mounjaro label lists NAION among reports for GLP-1 medicines as a group, so it covers tirzepatide too.7

Emergency number: 000

Side effects and risks in Australia

Canada

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.

Label: Health Canada’s Zepbound monograph added a NAION warning in June 2026.6 The Canadian Rybelsus monograph is the only label we checked that lists dry eye.5

Emergency number: 911

Side effects and risks in Canada

France

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).

Label: The answer above applies.

Emergency number: 15 or 112

Side effects and risks in France (in French)

Germany

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.

Label: The answer above applies.

Emergency number: 112

Side effects and risks in Germany (in German)

India

Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).

Label: We did not open an Indian label for this page, so it relies on the US, EU, UK, Canadian and Australian labels.

Emergency number: 112

Side effects and risks in India

Saudi Arabia

Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a Saudi label for this page, so it relies on the US, EU, UK, Canadian and Australian labels.

Emergency number: 997 or 911

Side effects and risks in Saudi Arabia (in Arabic)

United Arab Emirates

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.

Label: We did not open a UAE label for this page, so it relies on the US, EU, UK, Canadian and Australian labels.

Emergency number: 998 for an ambulance, or 999

Side effects and risks in the UAE

United Kingdom

Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.

Label: The UK Wegovy SmPC lists NAION but words the evidence more cautiously, saying studies “may indicate” a higher risk.10

Emergency number: 999

Side effects and risks in the UK

United States

Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).

Label: On 9 Nov 2026 the FDA told makers of all GLP-1 medicines, including Zepbound, Mounjaro, Wegovy and Ozempic, to add NAION to the warnings in their US labels.12 The US Wegovy and Zepbound labels we opened carry the retinopathy warning but did not yet list NAION.12

Emergency number: 911

Side effects and risks in the US

Get help now: call your local emergency number Sudden dizziness, weakness or change in vision is an emergency warning sign, according to the American College of Emergency Physicians.11 Emergency numbers: 911 in the US and Canada, 999 in the UK, 998 or 999 in the UAE, 000 in Australia, 112 in India and Germany, 15 or 112 in France, 997 or 911 in Saudi Arabia.

Contact your prescriber or a doctor right away if your eyesight worsens quickly or you lose part of your vision.6 Ask for an urgent appointment if you have blurred or double vision, see flashing lights or shapes, have a dark shadow moving across your vision, or have a painful red eye.9

Read the full picture

Related questions

Did this answer your question?

Sources

  1. US Wegovy (semaglutide) prescribing information, sections 5.8 and 17 and patient information. Novo Nordisk
  2. US Zepbound (tirzepatide) prescribing information, sections 5.8 and 17. Eli Lilly
  3. EU Mounjaro (tirzepatide) product information, section 4.4. European Medicines Agency
  4. EU Wegovy (semaglutide) product information, sections 4.4 and 4.8. European Medicines Agency
  5. Health Canada. Rybelsus (semaglutide tablets) product monograph, Table 3. pdf.hres.ca
  6. Health Canada. Zepbound (tirzepatide) product monograph. pdf.hres.ca
  7. Australian Mounjaro (tirzepatide) Product Information. medsinfo.com.au
  8. NHS. Low blood sugar (hypoglycaemia). nhs.uk
  9. NHS. Vision loss. nhs.uk
  10. UK Wegovy 2.4 mg FlexTouch (semaglutide) SmPC. emc
  11. MedlinePlus, US National Library of Medicine. Recognizing medical emergencies, giving the American College of Emergency Physicians’ warning signs. medlineplus.gov
  12. US Food and Drug Administration. FDA requires safety labeling changes for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) due to potential increased risk of rare but serious eye condition. Drug Safety Communication, 9 Nov 2026. fda.gov

Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error

How this answer was made. Written by the GLP Guidebook team from the sources above, all checked by Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write